Pralmorelin is a synthetic peptide growth hormone-releasing hormone (GHRH) analogue primarily investigated for the treatment of growth hormone deficiency and related conditions like pituitary dwarfism.… Read more
Pralmorelin is a synthetic peptide growth hormone-releasing hormone (GHRH) analogue primarily investigated for the treatment of growth hormone deficiency and related conditions like pituitary dwarfism. This category provides high-quality reference standards essential for analytical testing and method validation of this pharmaceutical compound. Laboratories rely on these materials to conduct rigorous impurity profiling, ensuring the identification and quantification of process-related impurities such as Hexapeptide-2. By utilizing these precise reference materials, including stable isotope labelled compounds, researchers can maintain the accuracy of quantitative analysis throughout the drug development lifecycle. These standards support critical quality control processes, allowing pharmaceutical scientists to verify the purity and stability of the active pharmaceutical ingredient during rigorous stability testing and regulatory assessments.